and loss of investment by our stockholders.·We are dependent on the success of our INOpulse product candidates and our ability to develop, obtain marketing approval for
business could be materially harmed.·We rely on Ikaria, as our single source supplier, for our supply of nitric oxide for the clinical trials of INOpulse.
to maintain or enforce the underlying patents, our competitive position and market share will be harmed.·We may seek to enter into collaborations with third parties for the development and commercialization of our product candidates.
Exceeding 4.99% ownership in shares of our outstanding common stock will trigger certain SEC filing requirements by such holder, including the submission of a Schedule 13G or Schedule 13D, as applicable, while such ownership percentage remains above 4.99%.Shares of Series A convertible preferred stock do not generally
offering are exercised).5Table of ContentsUse of proceedsWe intend to use the net proceeds from this offering for general corporate purposes, including manufacturing expenses, clinical trial expenses, research and development expenses and general and administrative expenses.
There is no established public trading market for the Series A convertible preferred stock or the Warrants to be issued in this offering, and we do not intend to apply to list such securities on any securities exchange or automated quotation system.The number of shares of
Our future funding requirements will depend on many factors, including:·the costs and timing of our research and development activities;·the progress and cost of our clinical trials and other research and development activities;·the cost and timing of securing manufacturing capabilities for our clinical product candidates
from this offering for general corporate purposes, including manufacturing expenses, clinical trial expenses, research and development
therapeutic discovery and development efforts, including conducting clinical trials for our product candidates, protecting our
therapeutic discovery and development efforts, including conducting clinical trials for our product candidates, protecting our
Use of inhaled nitric oxide is approved by the U.S. Food and Drug Administration, or the FDA, and certain other regulatory authorities to treat persistent PH of the newborn.
has marketed continuous-flow inhaled nitric oxide as INOmax for hospital use in this indication since FDA approval in 1999.
investigational new drug applications, or INDs, for INOpulse for the treatment of patients with PAH and PH-COPD.
certification covers the design, development and manufacture of inhaled pulsatile nitric oxide drug delivery systems including
in the use of inhaled nitric oxide in treating PH and in the development of drug-device combination product candidates.
the United States each year, indicating that physicians already use nitric oxide in some PAH patients.
INOpulse as an add-on or adjunctive therapy for PAH, where we believe it has the highest commercial potential.Clinical Development ProgramINOpulse for PAH is designated as a drug-device
that early pulsed delivery of nitric oxide could be directed specifically to the well-ventilated alveoli.Clinical Development ProgramINOpulse for PH-COPD is designated as a drug-device
Practices, or cGMP, is the only FDA-approved site for manufacturing medical nitric oxide in the world.To support business outside of the United States,
good laboratory practice, or GLP, regulations;·submission to the FDA of an investigational new drug application, or IND, which must take effect before human clinical trials
FDA as part of an NDA requesting approval to market the drug product for one or more indications.
labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug’s
the regulatory period during which the FDA cannot approve another application.Patent Term Restoration and ExtensionA patent claiming a new drug product or medical
including services related to regulatory matters, drug and device safety, clinical operations, biometrics and scientific affairs.
including services related to regulatory matters, drug and device safety, clinical operations, biometrics and scientific affairs.